Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1 18Phase 3 12Phase NA 10Phase 1/2 6Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Plasma cell 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 16Pemetrexed 15Cisplatin 15Erlotinib Hydrochloride 13icotinib 8Propofol 7Gefitinib 7Gemcitabine 6Docetaxel 6endostar protein 5Saline Solution 5Paclitaxel 5Nivolumab 5Endostatins 5tislelizumab 4lorlatinib 4anlotinib 4Vinorelbine 4Sevoflurane 4Drug Therapy 4Afatinib 4pembrolizumab 3durvalumab 3atezolizumab 3Zoledronic Acid 3Radiotherapy 3Dexamethasone 3Acetaminophen 3trilaciclib 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Specimen Handling × Thoracic × Clear all
NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4 Recruiting
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡